From 24th to 26th April, the 2024 International Food Safety and Health Conference (IFoFSH 2024), jointly organised by the Chinese Institute of Food Science and Technology and the Internationalof Food Science and Technology, convened in Beijing. Synaura Biotech, as China's leading HMO innovator, was invited to participate and delivered a presentation on the topic of ‘Management and Innovative Application Technologies for Functional Ingredients’.

Figure 1: 2024 International Forum on Food Safety and Health

Figure 2: Live footage from the conference venue

As an authoritative international gathering in the field of food safety and health, the Food Safety and Health Conference has consistently enjoyed strong support from relevant national authorities including the State Administration for Market Regulation, the Ministry of Industry and Information Technology, and the Ministry of Agriculture and Rural Affairs, alongside international organisations such as the World Health Organisation (WHO) and the Food and Agriculture Organisation (FAO). This conference brings together hundreds of experts and scholars from the food science and technology community and industry, alongside distinguished corporate representatives from both domestic and international spheres. Participants will collectively focus on technological innovation, engaging in intellectual exchange across nine thematic forums centred on the theme ‘New Quality Productivity: Advancing Health and Safety to Higher Standards’. Together, they will chart a course for the high-quality development of the food industry.

Figure 3: Ms Yao Fei delivering her presentation

Ms Yao Fei, Head of Applied Research and Development at Synaura Biotech, delivered a presentation entitled ‘Global Research and Application Landscape of HMOs’ on behalf of the company. The report traced the developmental trajectory of HMOs, offering an in-depth analysis of global research achievements, relevant patents, and current market applications both domestically and internationally. Furthermore, Ms Yao engaged with conference attendees in exploring the innovative application prospects of HMOs across global sectors including food, cosmetics, and healthcare.

Figure 4: Illustrating the Five Key Advantages of Synaura™ HMO

Synaura Biotech is China's leading indigenous developer and industrialiser of human milk oligosaccharides (HMOs), while also pioneering advancements in synthetic biology through mastery of cutting-edge synthetic biology technologies. Presently, Synaura has successfully established over ten distinct product lines spanning biomedicine, sustainable agriculture, and health foods. Extensively validated through practical applications, Synaura's HMOs are renowned for their superior quality, characterised by high purity, uniform particle size, and absence of acetic acid odour residue. Their adaptability to both dry and wet processing methods ensures application convenience. Synaura Biotech remains committed to independent innovation and industrial practice, dedicated to providing high-quality HMO raw materials to hundreds of millions of Chinese families, delivering enhanced health and care.